Mitral valve prolapse, once it has developed, does not go away on its own. The condition involves a structural change in the valve’s leaflets, and the body lacks a reliable mechanism to reverse that change. That said, MVP can appear to come and go depending on factors like hydration, body size, and even how strictly it is diagnosed, which has fueled a persistent belief that some people “outgrow” it. The reality is more layered than a simple yes or no, and the prognosis depends heavily on which version of MVP you have.
Why the Valve Does Not Repair Itself
In a healthy mitral valve, the leaflets are thin, flexible, and strong enough to snap shut tightly with every heartbeat. In MVP, the tissue undergoes what is called myxomatous degeneration: the normally organized layers of collagen and elastic fibers become disrupted, and the leaflets thicken and become floppy. This allows one or both leaflets to bulge (prolapse) back into the left atrium during contraction.
Research into what happens at the cellular level helps explain why this does not reverse. In myxomatous valves, the interstitial cells that normally maintain valve structure transform into a more active cell type that produces enzymes capable of breaking down the surrounding tissue matrix. These cells also trigger inflammation-related signals that perpetuate the remodeling process. Interestingly, the cells still retain the ability to produce new collagen, but this preserved capacity does not translate into a restoration of normal valve architecture.1PubMed. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves The new collagen is laid down in a disorganized way, within tissue that is already structurally compromised. Think of it like patching a stretched-out rubber band: you can add material, but you cannot restore the original tension and shape.
Because the underlying tissue change is structural and progressive, there is no medication, supplement, or lifestyle change that reverses myxomatous degeneration once it has taken hold. The valve does not heal back to its original form.
When MVP Appears to Come and Go
Despite being a permanent structural condition, MVP can seem intermittent. This is one of the most confusing aspects of the diagnosis, and it has real clinical consequences. The explanation comes down to how much blood is filling the heart at any given moment.
When your blood volume drops, such as during dehydration, the left ventricle becomes smaller. A smaller ventricle means the mitral valve leaflets have more slack relative to the space they need to cover, making prolapse more apparent. Conversely, when blood volume is high, the ventricle fills more completely, the leaflets are pulled taut, and the prolapse can become less noticeable or even undetectable on an echocardiogram. Research has shown that mild dehydration can induce echocardiographic signs of MVP in roughly half of healthy thin women who previously had normal cardiac findings, and that all of these changes resolved once the women were rehydrated.2PubMed. Gender differences in dehydration-induced mitral valve prolapse
A related study found that while hydrating people who already had MVP did not change the overall echocardiographic diagnosis, it did alter the sounds a doctor could hear with a stethoscope. The characteristic click and murmur of MVP would shift or disappear, potentially leading a clinician to think the condition had resolved.3American Heart Journal. Effects of hydration on mitral valve prolapse This means that the same person could be told they have MVP during a visit when they are slightly dehydrated and told everything looks normal a month later after drinking plenty of fluids.
Pregnancy offers another dramatic example. The roughly 40 to 50 percent increase in blood volume during pregnancy fills the heart more completely, often masking the prolapse. Some women are told their MVP has “gone away” during pregnancy, only to have it show up again after delivery when blood volume returns to baseline. The valve itself never changed; the conditions around it did.
Do Children and Adolescents Outgrow It?
This is one of the most common questions parents ask, and the answer is nuanced. A large systematic review and meta-analysis examining MVP prevalence across age groups found rates of about 0.5% in newborns, 1.8% in children, 2.7% in adolescents, and 2.0% in adults.4PubMed Central. Prevalence, progression, and clinical outcomes of mitral valve prolapse: a systematic review and meta-analysis That peak in adolescence, followed by a slightly lower rate in adulthood, has sometimes been interpreted as evidence that some teenagers outgrow the condition.
The truth is messier. Much of the apparent “resolution” in young people reflects the same volume-dependent phenomenon described above. Adolescents going through growth spurts are often tall and lean with relatively small hearts for their frame, conditions that make borderline prolapse more visible on an echo. As they fill out, gain muscle mass, and increase their blood volume, the prolapse may become less detectable without truly disappearing. Additionally, diagnostic criteria were tightened over the decades, meaning that some cases identified under older, more liberal standards would not qualify under current definitions. When those individuals are re-evaluated, they appear to have been “cured,” when in reality they were reclassified.
Genuine structural myxomatous changes, when present and confirmed, do not resolve with growth. Children and adolescents with clearly abnormal, thickened leaflets and significant regurgitation should be followed over time rather than assumed to be on a path to resolution.
What Makes MVP Get Worse
For most people with MVP, the condition stays mild and stable for years. But in a subset, it progresses to more significant mitral regurgitation, where the valve leaks enough to strain the heart. Understanding what drives progression matters because the factors are largely identifiable.
A study tracking MVP patients in a single community found that age and the initial severity of regurgitation were the two strongest independent predictors of whether the leak would worsen over time.5PubMed. Risk, determinants, and outcome implications of progression of mitral regurgitation after diagnosis of mitral valve prolapse in a single community Separate research confirmed that older age, higher body weight, hypertension, and being male were all independently associated with developing severe regurgitation.6PubMed. Severe mitral regurgitation due to mitral valve prolapse: risk factors for development, progression, and need for mitral valve surgery In men with MVP, higher blood pressure and body weight appeared to explain much of the gender difference in risk.
A more specific anatomical predictor also emerged from research on asymptomatic patients with moderate regurgitation: the diameter of the mitral annulus, the ring of tissue that anchors the valve. Over roughly four and a half years, half of asymptomatic patients who started with moderate regurgitation progressed to severe, while none of those starting with mild regurgitation did. An annular diameter greater than about 40 mm predicted that progression accurately.7PubMed. Predictive Factors for Progression of Mitral Regurgitation in Asymptomatic Patients With Mitral Valve Prolapse This finding is relevant because it means a routine echocardiogram can flag who needs closer monitoring well before symptoms develop.
The Long-Term Outlook
A landmark community-based study followed people with MVP over thousands of patient-years and stratified outcomes by risk factors. The results were reassuring for the majority: patients with zero or one secondary risk factor, which made up the largest group, had a 10-year mortality rate of about 5%, no different from what would be expected in the general population. Their rate of cardiovascular complications was low, around 0.5% per year.8PubMed. Natural history of asymptomatic mitral valve prolapse in the community
At the other end of the spectrum, patients with primary risk factors such as significant regurgitation or reduced heart function had 10-year mortality of about 45% and MVP-related event rates of 15% per year, a dramatically different picture. The middle group, with two or more secondary risk factors, had survival rates similar to the general population but noticeably higher rates of cardiovascular illness.
The takeaway is that “mitral valve prolapse” is not one disease with one prognosis. It ranges from a benign anatomical variant that never causes problems to a progressive valve disease that can lead to heart failure or the need for surgery. Knowing which group you fall into requires an echocardiogram and clinical assessment, not just a stethoscope.
Arrhythmias and Mitral Annulus Disjunction
One of the more concerning developments in MVP research over the past decade has been the recognition that a small subset of patients faces a heightened risk of dangerous heart rhythm disturbances, including sudden cardiac death. This “arrhythmic MVP” phenotype is distinct from the valve leak problem and involves electrical instability in the heart muscle itself.
Studies of sudden death victims and patients with significant arrhythmias have identified several pathological features in common: fibrosis in the papillary muscles and the inferobasal wall of the left ventricle, along with a structural abnormality called mitral annulus disjunction, where the base of the valve leaflet separates from the muscular wall of the ventricle.9PubMed. Mitral Valve Prolapse, Ventricular Arrhythmias, and Sudden Death This disjunction is most common in advanced myxomatous disease with involvement of both leaflets, and it appears to be linked to inflammation around the annulus and progressive fibrosis in the heart muscle below it.10European Heart Journal. Arrhythmic mitral valve prolapse and mitral annular disjunction: pathophysiology, risk stratification, and management
This does not mean that everyone with MVP should worry about sudden death. The vast majority of MVP patients never develop clinically significant arrhythmias. But the identification of this subset has changed how cardiologists evaluate certain patients, particularly those who report palpitations, fainting, or who have a family history of unexplained sudden death. Cardiac MRI has become an important tool for spotting the fibrosis and disjunction patterns associated with this risk.
When Surgery Can Fix the Problem
While MVP itself does not go away, surgery can effectively eliminate the regurgitation it causes when it becomes severe. Mitral valve repair, where the surgeon reshapes the native valve rather than replacing it, has become the preferred approach for degenerative MVP and has excellent long-term results. In one series, freedom from significant recurrent regurgitation was about 96% at five years and 91% at seven years, with freedom from reoperation at 93% over five years.11PubMed Central. Predictability and durability of mitral valve repair in patients with severe degenerative mitral regurgitation in medium sized centres
For patients who are too frail or too high-risk for open-heart surgery, percutaneous repair using a device clipped onto the valve leaflets through a catheter offers an alternative. Studies have shown stable clinical and echocardiographic results beyond one year, suggesting durable improvement even with this less invasive approach.12Open Heart. Two-year outcomes after percutaneous mitral valve repair with the MitraClip system: durability of the procedure and predictors of outcome
It is worth noting that surgery does not reverse the underlying myxomatous process. The repaired valve still has abnormal tissue. But a skilled repair restores competent valve function, eliminates the hemodynamic burden on the heart, and in most cases allows patients to return to normal activity without ongoing regurgitation.
Exercise and MVP
For the majority of people with MVP and no or mild regurgitation, regular physical activity is safe and encouraged. The standard advice gets more cautious, however, when markers of arrhythmic risk are present, such as significant ventricular arrhythmias, T-wave inversions on an ECG, or mitral annulus disjunction on imaging. Current guidelines recommend that individuals with any of these markers refrain from high-intensity exercise.13PubMed. Physical activity and exercise recommendations for patients with valvular heart disease
One concern that comes up often is whether years of intense exercise make MVP more dangerous. A study examining lifetime exercise dose in MVP patients found that higher cumulative exercise did not clearly increase the risk of serious ventricular arrhythmias beyond the risk already predicted by established factors. The researchers recommended maintaining the existing caution around high-intensity exercise but did not find reason to discourage moderate activity.14EP Europace. Lifetime exercise dose and ventricular arrhythmias in patients with mitral valve prolapse For most people with uncomplicated MVP, staying active is part of living well with the condition rather than something to fear.
Why Medications Do Not Make It Go Away
There is no medication that treats MVP itself. Beta-blockers, calcium channel blockers, and anti-anxiety drugs are sometimes prescribed for symptoms like palpitations, chest pain, and anxiety that can accompany MVP. But the evidence supporting their effectiveness is thin. A study of over 800 people with MVP-related symptoms found that 40% were taking one or more medications, yet the correlations between medication use and symptom improvement were very weak.15PubMed Central. Medication use and symptoms in individuals with mitral valve prolapse syndrome This does not mean these medications are useless for everyone, but it does mean the benefit is far from guaranteed, and the decision to use them should be weighed against side effects.
Lifestyle measures, particularly staying well hydrated, managing blood pressure, and maintaining a healthy weight, address some of the modifiable factors that can worsen regurgitation over time. These steps will not reverse the prolapse, but they may slow its progression and reduce symptom severity. Given that hypertension and higher body weight are independent predictors of worsening regurgitation, controlling them is one of the most practical things a person with MVP can do.
Body Shape and the MVP Connection
An observation that has held up over decades is the association between MVP and certain skeletal features, particularly pectus excavatum (a sunken breastbone) and a straight or flat thoracic spine. One study found that 62% of patients with idiopathic MVP had pectus excavatum, 17% had “straight back,” and 8% had significant scoliosis; overall, 75% had a definite thoracic skeletal abnormality.16The American Journal of Cardiology. Thoracic skeletal abnormalities in idiopathic mitral valve prolapse
This connection is thought to reflect a shared underlying connective tissue variation. MVP can occur as part of recognized connective tissue syndromes like Marfan syndrome, but the vast majority of cases are non-syndromic, appearing either in isolation or running in families without a full-blown syndrome.17PubMed Central. Genetics and pathophysiology of mitral valve prolapse For people with both MVP and a chest wall abnormality, the compressed thoracic shape may also exaggerate how the prolapse appears on imaging, since the heart sits in a narrower space and the valve geometry changes accordingly. This is another scenario where MVP might look worse on one scan than another purely because of positioning and body habitus, adding to the confusion about whether the condition is truly stable, worsening, or resolving.
The skeletal connection also has a practical implication. People with pectus excavatum or unusually straight spines who develop a murmur or click on a physical exam should have MVP ruled out with echocardiography rather than having the finding written off as benign. The association is strong enough that screening in this population catches real cases that might otherwise be missed.